Physician profile
John A Hunter
NPI 1568613065
$1,432.49
in general payments reported to CMS, 2019-2025
19 companies · $108 in 2025
The $108 reported for 2025 was less than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $277 · 2022: $122 · 2023: $507 · 2024: $419 · 2025: $108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,034.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,033.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $296.18 | 2022-2023 | Opsumit, Uptravi |
| Abbott Laboratories | $143.81 | 2024 | Cardiomems |
| Astrazeneca Pharmaceuticals Lp | $120.80 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $117.54 | 2024-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.20 | 2021 | |
| Merck Sharp & Dohme LLC | $96.27 | 2023-2025 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $94.13 | 2022-2023 | |
| Novo Nordisk INC | $91.85 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| E.R. Squibb & Sons, L.L.C. | $61.27 | 2023-2024 | Camzyos, Eliquis |
| Esperion Therapeutics, INC. | $45.35 | 2021 | |
| Johnson & Johnson Health Care Systems INC. | $44.22 | 2023 | Opsumit |
| Pfizer INC. | $39.57 | 2024 | |
| Amgen INC. | $32.40 | 2024 | Repatha |
| Sandoz INC. | $32.07 | 2023 | Treprostinil |
| Insmed, INC. | $29.30 | 2023 | Arikayce |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $25.65 | 2024 | |
| Kerecis Limited | $19.90 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Novartis Pharmaceuticals Corporation | $16.39 | 2024 | |
| United Therapeutics Corporation | $14.59 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hunter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.